ArticleEuropean journal of radiology open2023
A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST).
Giovanni Cappello et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it